News Article | August 9, 2017
A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. In Vitro Diagnostic Testing Services including Cardiac, Molecular Diagnostic and Genomic. Strategies & Trends. Price & Volume Forecasts by Laboratory Department. 2017 to 2022 - Latin America, Africa and Middle East Version" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2017 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. 1. Introduction and Market Definition 1.1 The Growing Demand for Clinical Testing 1.2 Defining the Opportunity 1.2.1 Volumes 1.2.2 Prices 1.2.3 Revenue Market Size 1.3 Methods and Sources 1.3.1 Authors 1.3.2 Sources 1.4 U.S. Medical Market and Clinical Laboratory Testing - Perspective 1.3.1 U.S. Medicare Expenditures for Clinical Testing 2. Overview of a Dynamic Market 2.1 Market Players - Roles & Impacts 2.1.1 Supplier/pharmaceutical 2.1.2 Independent lab specialized/esoteric 2.1.3 Independent lab national/regional 2.1.4 Independent lab analytical 2.1.5 Public National/regional lab 2.1.6 Hospital lab 2.1.7 Physician lab 2.1.5 Audit body 2.2 Segmentation - Different Approaches 2.2.1 Traditional Market Segmentation 2.2.2 Laboratory Focus and Segmentation 2.3 Structure of Clinical Testing Industry 2.3.1 The Hospital Lab - Share of the Pie 2.3.2 Key Role for Economies of Scale 2.3.3 Physician Office Lab's are Still Here 2.3.4 Physician's and POCT - Reviving Patient Service in China 2.4 Profiles of Key Companies 2.4.1 Quest Diagnostics 2.4.2 Laboratory Corporation of America 2.4.3 Lifelabs Medical Laboratory Services 2.4.4 ACM Medical Laboratory 2.4.5 Spectra Spectra Laboratories, Inc. 2.4.6 Bio-Reference Laboratories, Inc. 2.4.7 CompuNet Clinical Laboratories, LLC 2.4.5 Genzyme Corporation 2.4.9 Sonic Healthcare Limited 2.4.10 Exagen Diagnostics, Inc. 2.4.11 Clongen Laboratories LLC 2.4.12 Clinical Reference Laboratory, Inc. 2.4.13 Mid America Clinical Laboratories, LLC 2.4.14 Miraca Life Sciences, Inc. 2.4.15 Psychemedics Corp. 2.4.16 Aurora Diagnostics, LLC 2.4.17 DL Reference Laboratory 2.4.15 Myriad Genetics, Inc. 2.4.19 Bioscientia Institut fuer Medizinische Diagnostik GmbH 2.4.20 Acibadem Labmed Laboratory 2.4.21 Eurofins Scientific 2.4.22 The Doctor's Laboratory (Sonic Healthcare U.K.) 2.4.23 Pathology Inc. 2.4.24 Gribbles Pathology 2.4.25 B.P. CLINICAL LAB 2.4.26 Diagnsticos da Amrica (DASA) 2.4.27 American Bio-Clinical Laboratories, Int'l 2.4.25 Adicon Clinical Laboratories 2.4.29 Dian Diagnostics 2.4.30 Kingmed Diagnostics 2.4.31 Ascend Clinical, LLC 2.4.32 Unilabs SA 2.4.33 American Pathology Partners, Inc. 2.4.34 Integrated Regional Laboratories, Inc. 2.4.35 Viracor Laboratories 2.4.36 Neogenomics 2.4.37 Genomic Health, Inc. 2.4.35 ARUP Laboratories, Inc. 2.4.39 Enzo Biochem, Inc. 2.5 National and Regional Diversity 3. Trends Driving a Changing Market 3.1 Growth Is Pushed From Many Sides 3.1.1 Understanding the Impact of Aging Population. 3.1.2 Economic growth a Key Driver 3.1.3 Point of Care Testing can increase demand 3.1.4 Alternative Medicine Creates Testing Opportunity 3.1.5 Esoteric Testing Moving Mainstream 3.1.6 Genetic Based Testing Creates New Department and New Discipline 3.2 Factors At Work To Shrink The Market 3.2.1 Lower costs trend to continue 3.2.2 Economic or population contraction. 3.2.3 Testing usage analysis curtailing growth. 3.2.4 Wellness has a downside 3.2.5 Test Displacement Impacts Important 3.2.6 Point of Care Testing 3.3 Automation 3.3.2 Software as a Service 3.3.3 Physician Office and Access Systems 3.4 Environment and Evolution 3.5 Diagnostic Technology Development 3.5.1 Next Generation Sequencing Fuels a Revolution 3.5.2 Impact of NGS on pricing 3.5.3 POCT/Self Testing Disruptive Force 3.5.4 Pharmacogenomics Blurs Diagnosis and Treatment 3.5.5 CGES Testing, A Brave New World 3.5.6 Molecular Diagnostics Technologies At The Forefront of Growth 3.5.7 Biochips/Giant magneto resistance based assay 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section 4.2 LabCorp explores acquisition of clinical trials firm PPD 4.3 Digipath Enters into Letter of Intent to Acquire Clinical Lab Companies 4.4 PSP to acquire European medical lab services company 4.5 Mars, Incorporated to Acquire VCA Inc. 4.6 Caprion Biosciences Acquires the Immune Monitoring Laboratory from ImmuneHealth 4.7 Takara Bio USA Holdings and Rubicon Genomics Announce Merger Agreement 4.5 Instrumentation Laboratory Acquires CA Casyso AG 4.9 Schryver Medical Completes Acquisitions of Professional Clinical Laboratory, Inc. 4.10 Grail, Illumina's billion-dollar diagnostics startup 4.11 Grifols acquires Hologic's blood screening unit for $1.55bn 4.12 Bio-Rad Laboratories to buy US firm RainDance Technologies 4.13 Abbott Laboratories to buy St. Jude Medical for $25 billion 4.14 CombiMatrix Gets Serious About Potential M&A Options in Wake of $5M Offering 4.15 Abbott to Acquire Alere, Becoming Leader in Point of Care Testing 4.16 Achieving Dx Ambitions Key to Avant-Amarantus-Theranostics Merger 4.17 LabCorp Agrees to Acquire Assets of Pathology Inc. 4.15 NeoGenomics Completes Acquisition of Clarient, Inc. 4.19 FDA Gets Pushback on Move to Regulate Lab Developed Tests 4.20 Cancer Genetics, Inc. Announces Partnership 4.21 Theranos plans to close all its clinical labs 4.22 Forte Capital Lowers stake in Laboratory Corp. 4.23 US Oncology Network Selects Myriad Genetics 4.24 Pyxant Labs Commences Clinical Laboratory Testing Services 4.25 Viewics Launches Diabetes Management 4.26 Alpha Genomix And Rx30 Partner 4.27 LabCorp Doubles Testing Capacity Of Covance 4.25 LabCorp to acquire clinical laboratories from Mount Sinai 5. Country Markets - Latin America, Africa & The Middle East 2014 to 2022 5.1 Brazil 2014 to 2022 5.1.1 Clinical Chemistry - Volumes, Prices, Revenues 5.1.2 Microbiology - Volumes, Prices, Revenues 5.1.3 Hematology - Volumes, Prices, Revenues 5.1.4 Anatomic Pathology - Volumes, Prices, Revenues 5.1.5 Molecular Diagnostics - Volumes, Prices, Revenues 5.1.6 All Clinical Testing - Volumes, Prices, Revenues 5.1.7 Cardiac Biomarkers - Volumes, Prices, Revenues 5.1.5 Molecular Diagnostic Oncology - Volumes, Prices, Revenues 5.1.9 Molecular Diagnostic Genetics - Volumes, Prices, Revenues 5.2 Mexico 2014 to 2022 5.2.1 Clinical Chemistry - Volumes, Prices, Revenues 5.2.2 Microbiology - Volumes, Prices, Revenues 5.2.3 Hematology - Volumes, Prices, Revenues 5.2.4 Anatomic Pathology - Volumes, Prices, Revenues 5.2.5 Molecular Diagnostics - Volumes, Prices, Revenues 5.2.6 All Clinical Testing - Volumes, Prices, Revenues 5.2.7 Cardiac Biomarkers - Volumes, Prices, Revenues 5.2.5 Molecular Diagnostic Oncology - Volumes, Prices, Revenues 5.2.9 Molecular Diagnostic Genetics - Volumes, Prices, Revenues 5.3 Remainder of Latin America 2014 to 2022 5.3.1 Clinical Chemistry - Volumes, Prices, Revenues 5.3.2 Microbiology - Volumes, Prices, Revenues 5.3.3 Hematology - Volumes, Prices, Revenues 5.3.4 Anatomic Pathology - Volumes, Prices, Revenues 5.3.5 Molecular Diagnostics - Volumes, Prices, Revenues 5.3.6 All Clinical Testing - Volumes, Prices, Revenues 5.3.7 Cardiac Biomarkers - Volumes, Prices, Revenues 5.3.5 Molecular Diagnostic Oncology - Volumes, Prices, Revenues 5.3.9 Molecular Diagnostic Genetics - Volumes, Prices, Revenues 5.4 Africa & The Middle East 2014 to 2022 5.4.1 Clinical Chemistry - Volumes, Prices, Revenues 5.4.2 Microbiology - Volumes, Prices, Revenues 5.4.3 Hematology - Volumes, Prices, Revenues 5.4.4 Anatomic Pathology - Volumes, Prices, Revenues 5.4.5 Molecular Diagnostics - Volumes, Prices, Revenues 5.4.6 All Clinical Testing - Volumes, Prices, Revenues 5.4.7 Cardiac Biomarkers - Volumes, Prices, Revenues 5.4.5 Molecular Diagnostic Oncology - Volumes, Prices, Revenues 5.4.9 Molecular Diagnostic Genetics - Volumes, Prices, Revenues 6. The Future of the Clinical Laboratory For more information about this report visit https://www.researchandmarkets.com/research/cjlnfv/in_vitro Research and Markets Laura Wood, Senior Manager email@example.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
Kessell A.,Gribbles Pathology |
Hyatt A.,CSIRO |
Lehmann D.,Kangaroo Island Veterinary Clinic |
Shan S.,CSIRO |
And 12 more authors.
Emerging Infectious Diseases | Year: 2012
A novel virus, designated Cygnet River virus (CyRV), was isolated in embryonated eggs from Muscovy ducks in South Australia. CyRV morphologically resembles arenaviruses; however, sequencing identifi ed CyRV as an orthomyxovirus. The high mortality rate among ducks co-infected with salmonellae suggests that CyRV may be pathogenic, either alone or in concert with other infections.
Thompson M.,University of Queensland |
Fleeman L.M.,University of Queensland |
Kessell A.E,Gribbles Pathology |
Steenhard L.A,University of New South Wales |
Australian Veterinary Journal | Year: 2013
Background: Proximal renal tubulopathy was reported in Australian dogs with markedly increased frequency from September 2007. Methods: Two veterinarian-completed surveys were launched in response to an increased incidence of acquired proximal renal tubulopathy in dogs. The selection criterion for inclusion was glucosuria with blood glucose <10mmol/L. Data collected included signalment, presenting signs, history of feeding treats, results of urinalysis and blood tests, treatment and time to resolution of clinical signs. Results: A total of 108 affected dogs were studied. All had been fed the same brand of dried chicken treats, made in China, for a median of 12 weeks (range, 0.3-78 weeks). Small breeds (<10kg) accounted for 88% of cases. Common presenting signs included polyuria/polydipsia (76%), lethargy (73%), inappetence (65%) and vomiting (54%). Common biochemical findings included euglycaemia (74%; 71/96), hypoglycaemia (23%; 22/96), acidosis (77%; 20/26), hypokalaemia (45%; 38/84), hypophosphataemia (37%; 28/75) and azotaemia (27%; 23/85). In addition to discontinuation of treats, 64 dogs received medical treatment, including intravenous fluids (52%) and oral electrolyte, amino acid or vitamin supplements. Six dogs died or were euthanased. Two dogs were necropsied. Histopathological findings consisted of proximal tubular necrosis accompanied by regeneration. Time to resolution of clinical signs in 35 survivors available for follow-up was <2 weeks (n = 8), 2-4 weeks (n = 2), 5-7 weeks (n = 5) and 2-6 months (n = 10). Conclusion: Of the 108 dogs with acquired proximal renal tubulopathy contemporaneous with chicken treat consumption, most survived but many required aggressive supportive care. The treats likely contained a toxin targeting the proximal renal tubules. Diet history and urinalysis were vital for diagnosis. © 2013 Australian Veterinary Association.
Rezo A.,The Canberra Hospital |
Rezo A.,Capital Group |
Rezo A.,Australian National University |
Dahlstrom J.,The Canberra Hospital |
And 10 more authors.
Breast | Year: 2011
Purpose: Current AJCC/UICC staging of early breast cancer defines tumor stage using the largest focus, adding the suffix " (m)" to indicate multiplicity. This method may underestimate the total tumor burden in multifocal and multicentric breast cancer (MMBC). This study examines other measures of tumor size in MMBC to determine which provides the best fit in a multivariate model for survival outcomes. Patients and methods: This prospective cohort study used data from the Australian Capital Territory and New South Wales Breast Cancer Treatment Group database to identify 812 women with ipsilateral invasive breast cancer; 141 of these women had MMBC. The pathology slides of all women with MMBC were reviewed and all foci of invasive breast cancer were re-measured. The measures of interest were the diameter of the largest deposit, the aggregate diameter and the aggregate volume. These measures of tumor size were included with other clinicopathological features of MMBC in a multivariate analysis to assess their relationship with progression-free survival (PFS) and overall survival (OS). Results: Tumor size was associated with PFS and OS in MMBC using any of the three measures; however, the diameter of the largest deposit provided the best fit in the multivariate model for OS. Conclusion: Tumor size is an important prognostic factor for MMBC, and the diameter of the largest deposit provides a better fit in a multivariate model for OS than aggregate diameter and aggregate volume. Therefore, tumor size in MMBC should continue to be measured using the diameter of the largest deposit. © 2011.
Scheelings T.F.,Australian Wildlife Health Center |
Dobson E.C.,Gribbles Pathology |
Hooper C.,Gribbles Pathology
Journal of Zoo and Wildlife Medicine | Year: 2014
Two captive adult female Tasmanian devils (Sarcophilus harrisii) were investigated for pruritis and dermatitis. In both cases skin lesions consisted of multifocal, superficial patches of crusting, hyperkeratosis, and ulceration. Lesions started on the ventral surfaces of the animal but then appeared on the dorsum as the disease progressed. In both animals, a diagnosis of cutaneous T-cell lymphoma was made based on histologic appearance of skin biopsies using immunohistochemistry. Attempt at treatment with lomustine 20 mg p.o. once every 3 wk in one individual did not slow progression of the condition. As a result of their propensity for developing neoplastic conditions, the use of chemotherapeutic agents in Tasmanian devils warrants further investigation. © 2014 by American Association of Zoo Veterinarians.
PubMed | Gribbles Pathology and Australian Wildlife Health Center
Type: Journal Article | Journal: Australian veterinary journal | Year: 2015
Identification and characterisation of deaths is important for the veterinary management of both wild and captive animals. It is especially important as a tool for monitoring health and disease within populations of endangered species for which little information on morbidity and mortality is known. Investigations into the causes of death and other important necropsy findings were made in a captive population of the critically endangered mountain pygmy-possum (Burramys parvus).Necropsy records from January 2000-December 2013 were reviewed for all possums that had lived and died at Healesville Sanctuary (n=48).The average age of death of possums in this population was 4.7years. The most common histological change in mountain pygmy-possums was varying degrees of chronic progressive kidney disease (n=17). Of these cases, eight animals (47%) had histological changes suggesting the kidney disease was the likely cause of death. Other causes of death included neoplasia (n=5), necrotising pancreatitis (n=4), pneumonia (n=2), reproductive disease (n=2) and trauma (n=2). No cause of death was able to be identified in 33.3% (n=16) of cases. Hepatic lipidosis (n=5), pneumonia (n=2) and degenerative joint disease (n=2) were the most common comorbidities found.Progressive renal disease, often with secondary metastatic mineralisation, appears to be a significant cause of mortality in captive mountain pygmy-possums and further investigation into its pathophysiology, antemortem diagnosis and treatment is warranted.
Johnson D.W.,Princess Alexandra Hospital |
Jones G.R.D.,St Vincents Hospital |
Mathew T.H.,Kidney Health Australia |
Ludlow M.J.,Kidney Health Australia |
And 7 more authors.
Medical Journal of Australia | Year: 2012
Optimal detection and subsequent risk stratification of people with chronic kidney disease (CKD) requires simultaneous consideration of both kidney function (glomerular filtration rate [GFR]) and kidney damage (as indicated by albuminuria or proteinuria). Measurement of urinary albuminuria and proteinuria is hindered by a lack of standardisation regarding requesting, sample collection, reporting and interpretation of tests. A multidisciplinary working group was convened with the goal of developing and promoting recommendations that achieve consensus on these issues. The working group recommended that the preferred method for assessment of albuminuria in both diabetic and non-diabetic patients is urinary albumin-tocreatinine ratio (UACR) measurement in a first-void spot urine specimen. Where a first-void specimen is not possible or practical, a random spot urine specimen for UACR is acceptable. The working group recommended that adults with one or more risk factors for CKD should be assessed using UACR and estimated GFR every 1-2 years, depending on their risk-factor profile. Recommended testing algorithms and sex-specific cut-points for microalbuminuria and macroalbuminuria are provided. The working group recommended that all pathology laboratories in Australia should implement the relevant recommendations as a vital component of an integrated national approach to detection of CKD.
Haleagrahara N.,International Medical University |
Jackie T.,International Medical University |
Chakravarthi S.,International Medical University |
Rao M.,International Medical University |
Pasupathi T.,Gribbles Pathology
Food and Chemical Toxicology | Year: 2010
Several environmental toxins with toxic effects to the bone marrow have been identified. Pathology associated with lead intoxication is due to the cellular damage mediated by free radicals. In the current study, we examined the effect of Etlingera elatior extract on lead-induced changes in the oxidative biomarkers and histology of bone marrow of rats. Sprague-Dawley rats were exposed to 500. ppm lead acetate in their drinking water for 14. days. E. elatior extract was treated orally (100. mg/kg body weight) in combination with, or after lead acetate treatment. The results showed that there was a significant increase in lipid hydroperoxide, protein carbonyl content and a significant decrease in total antioxidants, super oxide dismutase, glutathione peroxidase and glutathione - S-transferase in bone marrow after lead acetate exposure. Treatment with E. elatior decreased lipid hydroperoxides and protein carbonyl contents and significantly increased total antioxidants and antioxidant enzymes. Treatments with E. elatior extract also reduced, lead-induced histopathological damage in bone marrow. In conclusion, these data suggest that E. elatior has a powerful antioxidant effect, and it protects the lead acetate-induced bone marrow oxidative damage in rats. © 2010 Elsevier Ltd.
Golbabapour S.,University of Malaya |
Pang W.W.,University of Malaya |
George J.,University of Malaya |
Pasupati T.,Gribbles Pathology |
And 2 more authors.
International Journal of Molecular Sciences | Year: 2011
The present study was undertaken to develop a rat model for monitoring the early development of breast cancer. Twelve female rats were divided into two groups of six rats that were either treated with N-methyl-N-nitrosourea to induce breast cancer or with bacterial lipopolysaccharide to induce inflammation. Serum samples taken from the rats prior to the treatment were used as controls. By the 14th week, presence of the tumor was detectable by contrast enhanced magnetic resonance imaging and confirmed by histopathology. When the serum proteins of the rats were examined by 2-dimensional electrophoresis (2-DE), no difference could be detected in the profiles of all proteins before and 18 weeks after administration of N-methyl-N-nitrosourea. However, higher expression of alpha-1B glycoprotein was detectable by 2-DE in serum samples of rats at the 18th week post-treatment with lipopolysaccharide. © 2011 by the authors; licensee MDPI, Basel, Switzerland.